TITLE:
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

CONDITION:
Carcinoma, Non-Small-Cell Lung

INTERVENTION:
gemcitabine/Eloxatin (GEMOX)

SUMMARY:

      The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin
      (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response
      and safety between the two drug combinations for the treatment of advanced non-small cell
      lung cancer (NSCLC).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Newly diagnosed, Stage IIIb or IV NSCLC, chemo or other systemic therapy naive

          -  One (1) unidimensionally measurable lesion

          -  ECOG Performance Status of 0 or 1, no peripheral neuropathy >Grade 1

          -  Patients with clinically stable brain metastases on a stable dose of (or no longer
             requiring) dexamethasone at registration will be eligible. Patients who have received
             cranial radiation for brain metastases must be at least 4 weeks from last radiation
             treatment.

          -  Recovery in full from any previous surgical procedure

          -  No history of an acute cardiac or CNS event within 6 months of entry or current
             clinical evidence of congestive heart failure or non-stable coronary artery disease

        Exclusion Criteria:

          -  Hypersensitivity to any of the 4 study drugs

          -  Concurrent immunotherapy or participation in any investigational drug study within 4
             weeks

          -  Serious uncontrolled intercurrent medical or psychiatric illness and organ allograft

          -  History of other malignancy within the last 5 years (except for squamous or basal
             cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial
             transitional cell carcinoma of the bladder)

          -  Patient is a pregnant or lactating female
      
